CRL

Business Profile & Competitive Position

Charles River Laboratories International, Inc. (CRL) sits in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. Its business is non-clinical drug development support: it supplies research model technologies, discovery and safety-assessment services (both GLP and non-GLP), and manufacturing support products. The company’s 2025 revenue of $4.0 billion was split across three reportable segments—Research Models and Services (RMS) at 21.1%, Discovery and Safety Assessment (DSA) at 59.8%, and Manufacturing Solutions at 19.1%.

The numbers currently tell a mixed competitive story. A negative net margin of -6.0% and a negative return on equity of -7.7% mean the business is not, at this snapshot, earning above its cost of capital. Those figures do not support a claim of a strong current economic moat; instead, they point to a company wrestling with either pricing pressure, volume inefficiency, or elevated operating leverage. Offsetting that is CRL’s global footprint of more than 120 sites across over 20 countries and its full-service positioning from target identification through non-clinical development. Scale and end-to-end breadth are real competitive assets, but the margin and ROE metrics show those assets have not translated into positive bottom-line returns in the most recent reporting window.

Financial Posture

CRL’s market capitalization is $13.4 billion, and the stock was recently trading at $278.26. The valuation metric that jumps out is the trailing P/E of -57.5, which reflects reported losses rather than a premium or discount in the usual sense. A negative P/E, a -6.0% net margin, and a -7.7% ROE all move together: the market is valuing a business that has recently been unprofitable. The beta of 1.41 indicates the stock has traded with meaningfully more volatility than the broader market.

Against that backdrop, technical convenience is fairly neutral: the RSI is 51.2, close to midpoint, and the 50-day exponential moving average is $260.10, so price is sitting roughly 7% above that shorter-term smoothing level. None of those figures imply a trading recommendation; they simply frame CRL as a higher-beta, currently loss-making diagnostics/research name trading above its recent average.

Strategic Priorities & Outlook

CRL’s most recent 10-K filing lays out a near-term agenda built on streamlining and integration. The company plans to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within the DSA and RMS segments. It is also merging Discovery Services and Safety Assessment into one overarching DSA organization with a combined sales force and leadership model. The stated goal is to become the scientific partner of choice by delivering a comprehensive, integrated portfolio that can accelerate biomedical research and therapeutic innovation.

On the growth side, CRL says it will continue seeking opportunities to expand Biologics Testing Solutions service offerings and facilities in the U.S. and Europe. A concrete recent step came in January 2026, when the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. The strategic message is therefore a blend of cost-driven footprint consolidation and targeted supply-chain/capability additions, particularly around biologics testing and research-model sourcing.

Macro & Geopolitical Exposure

As a Healthcare / Medical - Diagnostics & Research company, CRL is exposed to the regulatory frameworks that govern non-clinical research. GLP and non-GLP safety studies, animal model sourcing, and biologics testing are all subject to FDA, EMA, and comparable agency oversight. That means changes in regulatory stringency, animal-welfare rules, or import/export restrictions can directly affect operations.

Operating in more than 20 countries also brings currency translation risk and cross-border supply-chain complexity. The January 2026 Cambodia acquisition adds a specific Southeast Asia sourcing angle for non-human primates, tying CRL to regional supply-chain stability and wildlife-trade regulations. Broader macro drivers for the industry include biopharmaceutical R&D budgets, biotech funding availability, and interest-rate conditions that influence how aggressively drug developers outsource preclinical work. High sector sensitivity to the capital markets is consistent with CRL’s 1.41 beta.

Recent Developments

• On 2026-09-11, Charles River Laboratories announced it would present at Morgan Stanley and Baird conferences, as reported by both GuruFocus and BusinessWire.
• On 2026-09-10, Defense World reported that Amundi sold 360,913 shares of Charles River Laboratories International, a notable institutional flow worth tracking around the September reporting window.
• On 2026-09-08, The Motley Fool published an ETF-comparison piece asking whether the iShares Pharma ETF offers superior returns to Invesco’s Equal Weight Healthcare Fund, mentioning CRL within broader healthcare-fund context.

These items are thin on operational news, but the institutional sale and upcoming conference appearances are the kinds of headline events that can add short-term volatility to a higher-beta name.

Earnings Behavior & Post-Earnings Drift

CRL has been an unusually consistent earnings beater. Over the last eight reported quarters, the company has beaten estimates every time, for a 100% beat rate, with an average earnings surprise of 9.3%. The average 5-day post-earnings price move across those quarters is +1.24%, classified as an upward drift.

However, the last four prints show how uneven that drift can be despite the headline beat:

• 2026-08-05: actual EPS $3.02 vs. estimate $2.74 (10.2% surprise) — next-day move +1.84%, 5-day move +9.07%.
• 2026-05-07: actual EPS $2.06 vs. estimate $1.96 (5.1% surprise) — next-day move -2.23%, 5-day move -12.42%.
• 2026-02-18: actual EPS $2.39 vs. estimate $2.33 (2.6% surprise) — next-day move +3.95%, 5-day move +6.05%.
• 2025-11-05: actual EPS $2.43 vs. estimate $2.32 (4.7% surprise) — next-day move +1.90%, 5-day move +2.27%.

The takeaway is that beating the consensus has not guaranteed a positive reaction. The May 2026 report is the clearest example: a beat was met with a 5-day sell-off of 12.42%. The next scheduled report is 2026-11-04 before the open, with a consensus EPS estimate of $2.96. Traders monitoring post-earnings behavior should keep in mind both the long streak of beats and the wide variance in how the stock has drifted afterward.

For a deeper dive into CRL’s institutional positioning ahead of the November 4 report, readers can review the full institutional verdict on the ticker page.